Stocks Health care ABCL
NASDAQ · Health careAbCellera Biologics Inc. (ABCL)
AbCellera Biologics Inc. brought in $66.2M of revenue over the twelve months to June 30, 2026, up 101.3% from a year earlier. It posted a net loss of $164.7M. In fiscal 2025 capital spending exceeded operating cash flow by $174.1M. At June 30, 2026 it held $120.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 5, 2026.
What AbCellera Biologics Inc. does
AbCellera Biologics Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ABCL.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $75.1M | -$146.4M | -$0.49 | -$174.1M |
| 2024 | $28.8M | -$162.9M | -$0.55 | -$187M |
| 2023 | $38M | -$146.4M | -$0.51 | -$120.8M |
| 2022 | $485.4M | $158.5M | $0.50 | $206.7M |
| 2021 | $375.2M | $153.5M | $0.48 | $186.1M |
| 2021 | $233.2M | $118.9M | $0.45 | $13M |
Latest SEC filings
What AbCellera Biologics Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 13, 2026
- August 13, 2026
- August 11, 2026
- August 10, 2026
- August 7, 2026Other event 8-K
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026
- August 5, 2026
- July 29, 2026Other event 8-K
- July 6, 2026
- June 17, 2026Other event 8-K
Questions about ABCL
What does AbCellera Biologics Inc. do?
AbCellera Biologics Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ABCL.
Is AbCellera Biologics Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $164.7M on revenue of $66.2M.
How much revenue does AbCellera Biologics Inc. make?
Over the twelve months to June 30, 2026 AbCellera Biologics Inc. reported revenue of $66.2M. That is 101.3% more than a year earlier.
When did AbCellera Biologics Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 5, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from August 24, 2026.
Similar companies
Follow ABCL
Get an email when AbCellera Biologics Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow ABCL: get an email when it filesWhere the numbers come from
Financial figures are the values AbCellera Biologics Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.